AR041426A1 - Derivados de azol-pirimidina condensados; uso del compuesto para la preparacion de medicamentos - Google Patents
Derivados de azol-pirimidina condensados; uso del compuesto para la preparacion de medicamentosInfo
- Publication number
- AR041426A1 AR041426A1 ARP030103542A ARP030103542A AR041426A1 AR 041426 A1 AR041426 A1 AR 041426A1 AR P030103542 A ARP030103542 A AR P030103542A AR P030103542 A ARP030103542 A AR P030103542A AR 041426 A1 AR041426 A1 AR 041426A1
- Authority
- AR
- Argentina
- Prior art keywords
- amino
- alkyl
- optionally substituted
- aminocarbonyl
- halogen
- Prior art date
Links
- 239000003814 drug Substances 0.000 title abstract 3
- 150000001875 compounds Chemical class 0.000 title abstract 2
- DDWJFSYHYPDQEL-UHFFFAOYSA-N pyrimidine;1h-pyrrole Chemical class C=1C=CNC=1.C1=CN=CN=C1 DDWJFSYHYPDQEL-UHFFFAOYSA-N 0.000 title 1
- 125000004169 (C1-C6) alkyl group Chemical group 0.000 abstract 38
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 abstract 37
- 229910052757 nitrogen Inorganic materials 0.000 abstract 25
- 229910052736 halogen Inorganic materials 0.000 abstract 13
- -1 nitro, hydroxy, cyano, carboxy, amino Chemical group 0.000 abstract 13
- 125000004191 (C1-C6) alkoxy group Chemical group 0.000 abstract 9
- 125000003118 aryl group Chemical group 0.000 abstract 9
- 125000003917 carbamoyl group Chemical group [H]N([H])C(*)=O 0.000 abstract 9
- 150000002367 halogens Chemical group 0.000 abstract 7
- 125000001424 substituent group Chemical group 0.000 abstract 7
- 125000002252 acyl group Chemical group 0.000 abstract 6
- 125000005842 heteroatom Chemical group 0.000 abstract 6
- 229910052760 oxygen Inorganic materials 0.000 abstract 6
- 229920006395 saturated elastomer Polymers 0.000 abstract 6
- 229910052717 sulfur Inorganic materials 0.000 abstract 6
- 125000004454 (C1-C6) alkoxycarbonyl group Chemical group 0.000 abstract 5
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract 5
- 108091007960 PI3Ks Proteins 0.000 abstract 4
- 102000003993 Phosphatidylinositol 3-kinases Human genes 0.000 abstract 4
- 108090000430 Phosphatidylinositol 3-kinases Proteins 0.000 abstract 4
- 125000000217 alkyl group Chemical group 0.000 abstract 4
- 125000004103 aminoalkyl group Chemical group 0.000 abstract 4
- 229910052739 hydrogen Inorganic materials 0.000 abstract 4
- 239000001257 hydrogen Substances 0.000 abstract 4
- 125000002887 hydroxy group Chemical group [H]O* 0.000 abstract 4
- 125000004043 oxo group Chemical group O=* 0.000 abstract 4
- 125000006552 (C3-C8) cycloalkyl group Chemical group 0.000 abstract 3
- 125000001797 benzyl group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C([H])([H])* 0.000 abstract 3
- 201000010099 disease Diseases 0.000 abstract 3
- 230000000694 effects Effects 0.000 abstract 3
- 125000000623 heterocyclic group Chemical group 0.000 abstract 3
- 125000005113 hydroxyalkoxy group Chemical group 0.000 abstract 3
- 125000002373 5 membered heterocyclic group Chemical group 0.000 abstract 2
- 125000004070 6 membered heterocyclic group Chemical group 0.000 abstract 2
- 125000004171 alkoxy aryl group Chemical group 0.000 abstract 2
- 125000003545 alkoxy group Chemical group 0.000 abstract 2
- 125000004390 alkyl sulfonyl group Chemical group 0.000 abstract 2
- 125000002102 aryl alkyloxo group Chemical group 0.000 abstract 2
- 125000004104 aryloxy group Chemical group 0.000 abstract 2
- 125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 abstract 2
- 125000004093 cyano group Chemical group *C#N 0.000 abstract 2
- 208000035475 disorder Diseases 0.000 abstract 2
- 229940079593 drug Drugs 0.000 abstract 2
- 125000001072 heteroaryl group Chemical group 0.000 abstract 2
- 125000005553 heteroaryloxy group Chemical group 0.000 abstract 2
- 125000004435 hydrogen atom Chemical group [H]* 0.000 abstract 2
- 230000005764 inhibitory process Effects 0.000 abstract 2
- 208000028867 ischemia Diseases 0.000 abstract 2
- 238000011321 prophylaxis Methods 0.000 abstract 2
- 229940124530 sulfonamide Drugs 0.000 abstract 2
- 150000003456 sulfonamides Chemical class 0.000 abstract 2
- 238000011282 treatment Methods 0.000 abstract 2
- 125000006700 (C1-C6) alkylthio group Chemical group 0.000 abstract 1
- 208000024827 Alzheimer disease Diseases 0.000 abstract 1
- 201000001320 Atherosclerosis Diseases 0.000 abstract 1
- 206010003645 Atopy Diseases 0.000 abstract 1
- 208000023328 Basedow disease Diseases 0.000 abstract 1
- 125000006577 C1-C6 hydroxyalkyl group Chemical group 0.000 abstract 1
- 125000000882 C2-C6 alkenyl group Chemical group 0.000 abstract 1
- 206010007572 Cardiac hypertrophy Diseases 0.000 abstract 1
- 208000006029 Cardiomegaly Diseases 0.000 abstract 1
- 208000006545 Chronic Obstructive Pulmonary Disease Diseases 0.000 abstract 1
- 201000004624 Dermatitis Diseases 0.000 abstract 1
- 208000005189 Embolism Diseases 0.000 abstract 1
- 208000015023 Graves' disease Diseases 0.000 abstract 1
- 206010019280 Heart failures Diseases 0.000 abstract 1
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical group [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 abstract 1
- 208000012659 Joint disease Diseases 0.000 abstract 1
- 206010028980 Neoplasm Diseases 0.000 abstract 1
- 208000018737 Parkinson disease Diseases 0.000 abstract 1
- 102100036052 Phosphatidylinositol 4,5-bisphosphate 3-kinase catalytic subunit gamma isoform Human genes 0.000 abstract 1
- 101710096503 Phosphatidylinositol 4,5-bisphosphate 3-kinase catalytic subunit gamma isoform Proteins 0.000 abstract 1
- KAESVJOAVNADME-UHFFFAOYSA-N Pyrrole Chemical class C=1C=CNC=1 KAESVJOAVNADME-UHFFFAOYSA-N 0.000 abstract 1
- 208000001647 Renal Insufficiency Diseases 0.000 abstract 1
- 206010040070 Septic Shock Diseases 0.000 abstract 1
- 208000001435 Thromboembolism Diseases 0.000 abstract 1
- 239000004480 active ingredient Substances 0.000 abstract 1
- 125000004423 acyloxy group Chemical group 0.000 abstract 1
- 208000026935 allergic disease Diseases 0.000 abstract 1
- 125000006294 amino alkylene group Chemical group 0.000 abstract 1
- 125000006295 amino methylene group Chemical group [H]N(*)C([H])([H])* 0.000 abstract 1
- 125000005021 aminoalkenyl group Chemical group 0.000 abstract 1
- 125000004397 aminosulfonyl group Chemical group NS(=O)(=O)* 0.000 abstract 1
- 125000003710 aryl alkyl group Chemical group 0.000 abstract 1
- 208000006673 asthma Diseases 0.000 abstract 1
- 230000001363 autoimmune Effects 0.000 abstract 1
- 201000011510 cancer Diseases 0.000 abstract 1
- 125000004181 carboxyalkyl group Chemical group 0.000 abstract 1
- 206010012601 diabetes mellitus Diseases 0.000 abstract 1
- 125000002485 formyl group Chemical group [H]C(*)=O 0.000 abstract 1
- 150000002431 hydrogen Chemical group 0.000 abstract 1
- 125000002768 hydroxyalkyl group Chemical group 0.000 abstract 1
- 230000004957 immunoregulator effect Effects 0.000 abstract 1
- 230000002757 inflammatory effect Effects 0.000 abstract 1
- 201000006370 kidney failure Diseases 0.000 abstract 1
- 238000002483 medication Methods 0.000 abstract 1
- 125000000325 methylidene group Chemical group [H]C([H])=* 0.000 abstract 1
- 230000002107 myocardial effect Effects 0.000 abstract 1
- 208000015122 neurodegenerative disease Diseases 0.000 abstract 1
- 230000007170 pathology Effects 0.000 abstract 1
- 125000003884 phenylalkyl group Chemical group 0.000 abstract 1
- 208000002815 pulmonary hypertension Diseases 0.000 abstract 1
- 125000004076 pyridyl group Chemical group 0.000 abstract 1
- 206010039073 rheumatoid arthritis Diseases 0.000 abstract 1
- 206010039083 rhinitis Diseases 0.000 abstract 1
- 150000003839 salts Chemical class 0.000 abstract 1
- 239000000126 substance Substances 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/12—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains three hetero rings
- C07D471/14—Ortho-condensed systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/02—Nasal agents, e.g. decongestants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/08—Antiallergic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/14—Drugs for disorders of the endocrine system of the thyroid hormones, e.g. T3, T4
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/12—Antihypertensives
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
- C07D487/04—Ortho-condensed systems
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Public Health (AREA)
- General Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Immunology (AREA)
- Cardiology (AREA)
- Heart & Thoracic Surgery (AREA)
- Pulmonology (AREA)
- Diabetes (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Urology & Nephrology (AREA)
- Rheumatology (AREA)
- Hospice & Palliative Care (AREA)
- Endocrinology (AREA)
- Pain & Pain Management (AREA)
- Psychiatry (AREA)
- Vascular Medicine (AREA)
- Emergency Medicine (AREA)
- Hematology (AREA)
- Obesity (AREA)
- Otolaryngology (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Physical Education & Sports Medicine (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
Abstract
Los presentes compuestos son derivados de azolpirimidina condensados, los cuales presentan una mayor potencia para la inhibición de la fosfatidilinositol-3-quinasa (PI3K), especialmente para la inhibición de la PI3K-gama y pueden usarse para la profilaxis y tratamiento de enfermedades asociadas con la actividad de PI3K y particularmente con la actividad de PI3K-gama. Más específicamente, éstos derivados de azol son los ingredientes activos de medicamentos útiles para el tratamiento y profilaxis de las siguientes enfermedades: trastornos inflamatorios e inmunorreguladores tales como asma, dermatitis, atópica, rinitis, enfermedades alérgicas, enfermedad pulmonar obstructiva crónica (COPD), choque séptico, enfermedades de las articulaciones, patologías autoinmunes tales como artritis reumatoide, y enfermedad de Graves, cáncer, trastornos de contractilidad del miocardio, insuficiencia cardíaca, tromboembolia, isquemia y aterosclerosis. Estos medicamentos también son útiles para la hipertensión pulmonar, insuficiencia renal, hipertrofia cardíaca así como trastornos neurodegenerativos tales como enfermedad de Parkinson, enfermedad de Alzheimer, diabetes e isquemia focal, ya que las enfermedades también están relacionadas con la actividad de PI3K en un ser humano o animal. Reivindicación 1: Un derivado de azolpirimidina condensado de fórmula (1), su forma tautomérica o estereoisomérica, o una sal del mismo, donde: X representa CR5R6 o NH; Y1 representa CR3 o N; el enlace químico entre Y2 puntos línea Y3 representa un enlace sencillo o un doble enlace, con la condición de que cuando Y2 puntos línea Y3 representa un doble enlace; Y2 e Y3 representa independientemente CR4 o N, y cuando Y2 puntos línea Y3 representa un enlace sencillo, Y2 e Y3 representa independientemente CR3R4 o NR4; Z1, Z2, Z3 y Z4 representan independientemente CH, CR2 o N; R1 representa arilo que tiene opcionalmente de 1 a 3 sustituyentes seleccionados entre R11, cicloalquilo C3-8 que tiene opcionalmente de 1 a 3 sustituyentes seleccionados entre R11, alquilo C1-6 opcionalmente sustituido con arilo, heteroarilo, alcoxiarilo C1-6, ariloxi, heteroariloxi o uno o más halógenos, alcoxi C1-6 opcionalmente sustituido con carboxi, arilo, heteroarilo, alcoxiarilo C1-6, ariloxi, heteroariloxi o uno o más halógenos, o un anillo heterocíclico mono- o bi-cíclico de 3 a 15 miembros que está saturado o insaturado, que tiene opcionalmente de 1 a 3 sustituyentes seleccionados entre R11, y contiene de 1 a 3 heteroátomos seleccionados entre el grupo compuesto por N, O y S; donde R11 representa halógeno, nitro, hidroxi, ciano, carboxi, amino, N-(alquil C1-6)amino, N-(hidroxialquil C1-6)amino, N,N-di(alquil C1-6)amino, N-(acil C1-6)amino, N-(formil)-N-(alquil C1-6)amino, N-(alcanosulfonil C1-6)amino, N-(carboxialquil C1-6)-N-(alquil C1-6)amino, N-(alcoxicarbonil C1-6)amino, N-[N,N-di(alquil C1-6)aminometileno]amino, N-[N,N-di(alquil C1-6)amino(alquil C1-6)metileno]amino, N-[N,N-di(alquil C1-6)aminoalquenil C2-6]amino, aminocarbonilo, N-(alquil C1-6)aminocarbonilo, N,N-di(alquil C1-6)aminocarbonilo, cicloalquilo C3-8, alquiltio C1-6, alcanosulfonilo C1-6, sulfamoilo, alcoxicarbonilo C1-6, N-arilamino donde dicho resto arilo tiene opcionalmente de 1 a 3 sustituyentes seleccionados entre R101, N-(arilalquil C1-6)amino, donde dicho reto arilo tiene opcionalmente de 1 a 3 sustituyentes seleccionados entre R101, arilalcoxi(C1-6)-carbonilo donde dicho resto arilo tiene opcionalmente de 1 a 3 sustituyentes seleccionados entre R101, alquilo C1-6 opcionalmente sustituido cono mono-, di- o tri-halógeno, amino, N-(alquil C1-6)amino o N,N-di(alquil C1-6)amino, alcoxi C1-6 opcionalmente sustituido cono mono-, di- o tri-halógeno, N-(alquil C1-6)sulfonamida o N-(aril)sulfonamida, o un anillo saturado o insaturado de 5 a 7 miembros que tiene de 1 a 3 heteroátomos seleccionados entre el grupo compuesto por O, S y N, y que tiene opcionalmente de 1 a 3 sustituyentes seleccionados entre R101; donde R01 representa halógeno, carboxi, amino, N-(alquil C1-6)amino, N,N-di(alquil C1-6)amino, aminocarbonilo, N-(alquil C1-6)aminocarbonilo, N,N-di(alquil C1-6)aminocarbonilo, piridilo, alquilo C1-6 opcionalmente sustituido con ciano o mono- di.- o tri-halógeno, y alcoxi C1-6 opcionalmente sustituido con ciano, carboxi, amino, N-(alquil C1-6)amino, N,N-di(alquil C1-6)amino, aminocarbonilo, N-(alquil C1-6)aminocarbonilo, N,N-di(alquil C1-6)aminocarbonilo o mono-, di- o tri-halógeno; R2 representa hidroxi, halógeno, nitro, ciano, amino, N-(alquil C1-6)amino, N,N-di(alquil C1-6)amino, N-(hidroxialquil C1-6)amino, N-(hidroxialquil C1-6)-N-(alquil C1-6)amino, aciloxi C1-6, aminoaciloxi C1-6, alquenilo C2-6, arilo, un anillo heterocíclico saturado o insaturado de 5-7 miembros que tiene de 1 a 3 heteroátomos seleccionados entre el grupo compuesto por O, S y N, y opcionalmente sustituido con hidroxi, alquilo c1-6, alcoxi C1-6, oxo, amino, aminoalquilo C1-6, N-(alquil C1-6)amino, N,N-di(alquil C1-6)amino, N-(acil C1-6)amino, N-(alquil c1-6)carbonilamino, fenilo, fenilalquilo C1-6, carboxi, alcoxicarbonilo C1-6, aminocarbonilo, N-(alquil C1-6)aminocarbonilo o N,N-di(alquil C1-6)amino, -C(O)-R20; donde R20 representa alquilo C1-6, alcoxi C1-6, amino, N-(alquil C1-6)amino, N,N-di(alquil C1-6)amino, N-(acil C1-6)amino o un anillo heterocíclico saturado o insaturado de 5-7 miembros que tiene de 1 a 3 heteroátomos seleccionados entre el grupo compuesto por O, S y N, y opcionalmente sustituido con alquilo C1-6, alcoxi C1-6, oxo, amino N-(alquil C1-6)amino, N,N-di(alquil C1-6)amino, N-(acil C1-6)amino, fenilo o bencilo, alquilo C1-6 opcionalmente sustituido con R21 o alcoxi C1-6 opcionalmente sustituido con R21; donde R21 representa ciano, mono-, di- o tri-halógeno, hidroxi, amino, N-(alquil C1-6)amino, N,N-di(alquil C1-6)amino, N-(hidroxialquil C1-6)amino, N-(halofenilalquil C1-6)amino, aminoalquilenilo C2-6, alcoxi C1-6, hidroxialcoxi C1-6,-C(O)-R21, -NHC(O)-R201, cicloalquilo C3-8, isoindonilo, ftalimidilo 2-oxo-1,3-oxazolidinilo, arilo o un anillo heterocíclico saturado o insaturado de 5 ó 6 miembros que tiene de 1 a 4 heteroátomos seleccionados entre el grupo compuesto por O, S o N opcionalmente sustituido con hidroxi, alquilo C1-6, alcoxi C1-6, alcoxicarbonilo C1-6, hidroxialcoxi C1-6, oxo, amino, aminoalquilo C1-6, N-(alquil C1-6)amino, N,N-di(alquil C1-6)amino, N-(acil C1-6)amino o bencilo; donde R201 representa hidroxi, amino, N-(alquil C1-6)amino, N,N-(alquil C1-6)amino, N-(halofenilalquil C1-6)amino, alquilo C1-6, aminoalquilo C1-6, aminoalquilenilo C2-6, alcoxi C1-6, un anillo heterocíclico saturado o insaturado de 5 ó 6 miembros que tiene de 1 a 4 heteroátomos seleccionados entre el grupo compuesto por O, S y N opcionalmente sustituidos con hidroxi, alquilo C1-6, alcoxi C1-6, alcoxicarbonilo C1-6, hidroxialcoxi c1-6, oxo, amino, N-(alquil C1-6)amino, N,N-di(alquil C1-6)amino, N-(acil C1-6)amino o bencilo; R3 representa hidrógeno, halógeno, aminocarbonilo o alquilo C1-6 opcionalmente sustituido con arilalcoxi C1-6 o mono-, di- o tri-halógeno; R4 representa hidrógeno o alquilo C1-6; R5 representa hidrógeno o alquilo C1-6; y R6 representa halógeno, hidrógeno o alquilo C1-6.
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP02021861 | 2002-09-30 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| AR041426A1 true AR041426A1 (es) | 2005-05-18 |
Family
ID=32039115
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| ARP030103542A AR041426A1 (es) | 2002-09-30 | 2003-09-29 | Derivados de azol-pirimidina condensados; uso del compuesto para la preparacion de medicamentos |
| ARP090102458A AR072458A2 (es) | 2002-09-30 | 2009-07-01 | Derivados de azol-pirimidina condensados, composiciones farmaceuticas que los contienen y su uso para inhibir la actividad pi3k-? |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| ARP090102458A AR072458A2 (es) | 2002-09-30 | 2009-07-01 | Derivados de azol-pirimidina condensados, composiciones farmaceuticas que los contienen y su uso para inhibir la actividad pi3k-? |
Country Status (32)
| Country | Link |
|---|---|
| US (2) | US7511041B2 (es) |
| EP (2) | EP1549652B1 (es) |
| JP (1) | JP4790266B2 (es) |
| KR (1) | KR101059652B1 (es) |
| CN (1) | CN100384846C (es) |
| AR (2) | AR041426A1 (es) |
| AT (2) | ATE411996T1 (es) |
| AU (1) | AU2003293310B2 (es) |
| BR (1) | BRPI0314830B8 (es) |
| CA (1) | CA2499134C (es) |
| CY (2) | CY1109790T1 (es) |
| DE (1) | DE60324296D1 (es) |
| DK (2) | DK1549652T3 (es) |
| EC (2) | ECSP055768A (es) |
| ES (2) | ES2367141T3 (es) |
| HR (2) | HRP20131159B1 (es) |
| IL (1) | IL166855A (es) |
| MA (1) | MA27483A1 (es) |
| MX (1) | MXPA05001808A (es) |
| MY (1) | MY140756A (es) |
| NO (1) | NO331457B1 (es) |
| NZ (1) | NZ539062A (es) |
| PE (1) | PE20050089A1 (es) |
| PL (1) | PL226562B1 (es) |
| PT (2) | PT1549652E (es) |
| RU (1) | RU2326881C9 (es) |
| SI (2) | SI2042504T1 (es) |
| TW (1) | TWI327570B (es) |
| UA (1) | UA82205C2 (es) |
| UY (1) | UY28001A1 (es) |
| WO (1) | WO2004029055A1 (es) |
| ZA (1) | ZA200503306B (es) |
Families Citing this family (87)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US6667300B2 (en) | 2000-04-25 | 2003-12-23 | Icos Corporation | Inhibitors of human phosphatidylinositol 3-kinase delta |
| CN100554249C (zh) | 2003-08-29 | 2009-10-28 | 三井化学株式会社 | 农园艺用杀虫剂及其使用方法 |
| PT2612862T (pt) | 2004-05-13 | 2016-12-15 | Icos Corp | Quinazolinonas como inibidores de fosfatidilinositol 3-quinase delta humana |
| RU2403258C2 (ru) | 2004-10-07 | 2010-11-10 | Бёрингер Ингельхайм Интернациональ Гмбх | Тиазолилдигидроиндазолы |
| WO2006040645A1 (en) * | 2004-10-11 | 2006-04-20 | Ranbaxy Laboratories Limited | N-(3,5-dichloropyridin-4-yl)-2,4,5-alkoxy and 2,3,4-alkoxy benzamide derivatives as pde-iv (phophodiesterase type-iv) inhibitors for the treatment of inflammatory diseases such as asthma |
| AU2006236621B2 (en) | 2005-04-14 | 2011-10-06 | The Trustees Of Boston University | Diagnostic for lung disorders using class prediction |
| WO2007016979A2 (en) * | 2005-07-29 | 2007-02-15 | 4Sc Ag | NOVEL HETEROCYCLIC NF-κB INHIBITORS |
| EP1999472A2 (en) | 2006-03-09 | 2008-12-10 | The Trustees Of Boston University | Diagnostic and prognostic methods for lung disorders using gene expression profiles from nose epithelial cells |
| US7691868B2 (en) | 2006-04-06 | 2010-04-06 | Boehringer Ingelheim International Gmbh | Thiazolyl-dihydro-quinazoline |
| US7517995B2 (en) * | 2006-04-06 | 2009-04-14 | Boehringer Ingelheim International Gmbh | Thiazolyl-dihydro-cyclopentapyrazole |
| PL2041139T3 (pl) * | 2006-04-26 | 2012-05-31 | Hoffmann La Roche | Związki farmaceutyczne |
| WO2008064244A2 (en) * | 2006-11-20 | 2008-05-29 | The Trustees Of Columbia University In The City Of New York | Phosphoinositide modulation for the treatment of neurodegenerative diseases |
| AR064106A1 (es) * | 2006-12-05 | 2009-03-11 | Bayer Schering Pharma Ag | Derivados de 2,3-dihidroimidazo [1,2-c] quinazolina sustituida utiles para el tratamiento de enfermedades y trastornos hiper-proliferativos asociados con la angiogenesis |
| EP1953163A1 (en) * | 2007-02-01 | 2008-08-06 | Boehringer Ingelheim Pharma GmbH & Co. KG | Pteridinone derivatives as PI3-kinases inhibitors |
| WO2008148023A2 (en) * | 2007-05-23 | 2008-12-04 | Medical College Of Georgia Research Institute, Inc. | Compositions and methods for treating neurological disorders |
| US20100204222A1 (en) * | 2007-09-17 | 2010-08-12 | GlaxoSmithKline, LLC | Pyridopyrimidine derivatives as p13 kinase inhibitors |
| JP2010538680A (ja) * | 2007-09-19 | 2010-12-16 | ザ トラスティーズ オブ ボストン ユニバーシティー | 肺疾患に対する薬剤開発のための新規経路の同定 |
| WO2009091550A2 (en) * | 2008-01-14 | 2009-07-23 | Bayer Healthcare Llc | Sulfone substituted 2,3-dihydroimidazo [1,2-c] quinazoline derivatives useful for treating hyper-proliferative disorders and diseases with angiogenesis |
| EP2250160B1 (en) | 2008-01-25 | 2015-11-11 | Millennium Pharmaceuticals, Inc. | Thiophenes and their use as phosphatidylinositol 3-kinase (pi3k) inhibitors |
| US20090227575A1 (en) * | 2008-03-04 | 2009-09-10 | Wyeth | 7H-PYRROLO[2,3-H]QUINAZOLINE COMPOUNDS, THEIR USE AS mTOR KINASE AND PI3 KINASE INHIBITORS, AND THEIR SYNTHESIS |
| US20110105457A1 (en) * | 2008-04-18 | 2011-05-05 | Shionogi & Co., Ltd. | Heterocyclic compound having inhibitory activity on pi3k |
| EP2303890A4 (en) * | 2008-06-19 | 2012-04-11 | Progenics Pharm Inc | INHIBITORS OF PHOSPHATIDYLINOSITE-3-KINASE |
| EP2168582A1 (en) | 2008-09-24 | 2010-03-31 | Bayer Schering Pharma Aktiengesellschaft | Combinations of substituted 2,3-dihydroimidazo[1,2-c]quinazolines |
| EP2168583A1 (en) * | 2008-09-24 | 2010-03-31 | Bayer Schering Pharma Aktiengesellschaft | Use of substituted 2,3-dihydroimidazo[1,2-c]quinazolines for the treatment of myeloma |
| CA2735932C (en) * | 2008-09-30 | 2013-07-09 | Pfizer Inc. | Imidazo[1,5]naphthyridine compounds, their pharmaceutical use and compositions |
| PL2364983T3 (pl) * | 2008-11-11 | 2014-04-30 | Jeil Pharmaceutical Co Ltd | Nowa pochodna tricykliczna lub jej farmaceutycznie dopuszczalne sole, sposób jej wytwarzania, oraz zawierająca ją kompozycja farmaceutyczna |
| WO2010057048A1 (en) | 2008-11-13 | 2010-05-20 | Calistoga Pharmaceuticals Inc. | Therapies for hematologic malignancies |
| US9492449B2 (en) | 2008-11-13 | 2016-11-15 | Gilead Calistoga Llc | Therapies for hematologic malignancies |
| US10236078B2 (en) | 2008-11-17 | 2019-03-19 | Veracyte, Inc. | Methods for processing or analyzing a sample of thyroid tissue |
| US9495515B1 (en) | 2009-12-09 | 2016-11-15 | Veracyte, Inc. | Algorithms for disease diagnostics |
| US9090601B2 (en) | 2009-01-30 | 2015-07-28 | Millennium Pharmaceuticals, Inc. | Thiazole derivatives |
| US9139589B2 (en) | 2009-01-30 | 2015-09-22 | Millennium Pharmaceuticals, Inc. | Heteroaryls and uses thereof |
| MX2011009955A (es) | 2009-03-24 | 2011-11-18 | Gilead Calistoga Llc | Atropisomeros de derivados de 2-purinil-3-tolil-quinazolinona y metodos de uso. |
| AP2011005956A0 (en) | 2009-04-20 | 2011-10-31 | Gilead Calistoga Llc | Methods of treatment for solid tumors. |
| ES2876933T3 (es) * | 2009-04-30 | 2021-11-15 | Glaxo Group Ltd | Indazoles sustituidos con oxazol como inhibidores de PI3-cinasas |
| US8669057B2 (en) | 2009-05-07 | 2014-03-11 | Veracyte, Inc. | Methods and compositions for diagnosis of thyroid conditions |
| AU2010276160A1 (en) | 2009-07-21 | 2012-02-09 | Gilead Calistoga Llc | Treatment of liver disorders with PI3K inhibitors |
| US20110230476A1 (en) * | 2009-09-09 | 2011-09-22 | Avila Therapeutics, Inc. | Pi3 kinase inhibitors and uses thereof |
| CA2796253A1 (en) | 2010-04-16 | 2011-10-20 | Bayer Intellectual Property Gmbh | Substituted 2,3-dihydroimidazo[1,2-c]quinazoline-containing combinations |
| US9062038B2 (en) | 2010-08-11 | 2015-06-23 | Millennium Pharmaceuticals, Inc. | Heteroaryls and uses thereof |
| AU2011310532B2 (en) | 2010-10-01 | 2016-01-14 | Bayer Intellectual Property Gmbh | Substituted N-(2-arylamino)aryl sulfonamide-containing combinations |
| UA113280C2 (xx) * | 2010-11-11 | 2017-01-10 | АМІНОСПИРТЗАМІЩЕНІ ПОХІДНІ 2,3-ДИГІДРОІМІДАЗО$1,2-c]ХІНАЗОЛІНУ, ПРИДАТНІ ДЛЯ ЛІКУВАННЯ ГІПЕРПРОЛІФЕРАТИВНИХ ПОРУШЕНЬ І ЗАХВОРЮВАНЬ, ПОВ'ЯЗАНИХ З АНГІОГЕНЕЗОМ | |
| CA2817287A1 (en) | 2010-11-11 | 2012-05-18 | Bayer Intellectual Property Gmbh | Arylaminoalcohol-substituted 2,3-dihydroimidazo[1,2-c]quinolines |
| CA2817312A1 (en) | 2010-11-11 | 2012-05-18 | Bayer Intellectual Property Gmbh | Alkoxy-substituted 2,3-dihydroimidazo[1,2-c]quinazolines |
| EP2508525A1 (en) * | 2011-04-05 | 2012-10-10 | Bayer Pharma Aktiengesellschaft | Substituted 2,3-dihydroimidazo[1,2-c]quinazoline salts |
| JO3733B1 (ar) | 2011-04-05 | 2021-01-31 | Bayer Ip Gmbh | استخدام 3,2-دايهيدروايميدازو[1, 2 -c]كوينازولينات مستبدلة |
| MD20140100A2 (ro) | 2012-03-05 | 2015-01-31 | Gilead Calistoga Llc | Forme polimorfe ale (S)-2-(1-(9H-purin-6-ilamino)propil)-5-fluoro-3-fenilchinazolin-4(3H)-onei |
| EP2968988A4 (en) | 2013-03-14 | 2016-11-16 | Allegro Diagnostics Corp | METHOD FOR EVALUATING A COPD STATUS |
| US11976329B2 (en) | 2013-03-15 | 2024-05-07 | Veracyte, Inc. | Methods and systems for detecting usual interstitial pneumonia |
| WO2014144850A1 (en) | 2013-03-15 | 2014-09-18 | Genentech, Inc. | Methods of treating cancer and preventing cancer drug resistance |
| UA119537C2 (uk) | 2013-04-08 | 2019-07-10 | Байєр Фарма Акцієнгезелльшафт | ЗАСТОСУВАННЯ ЗАМІЩЕНИХ 2,3-ДИГІДРОІМІДАЗО[1,2-c]ХІНАЗОЛІНІВ ДЛЯ ЛІКУВАННЯ ЛІМФОМ |
| PE20161063A1 (es) | 2013-05-01 | 2016-10-22 | Hoffmann La Roche | Compuestos de biheteroarilo y usos de los mismos |
| WO2015027431A1 (en) * | 2013-08-29 | 2015-03-05 | Merck Sharp & Dohme Corp. | 2,2-difluorodioxolo a2a receptor antagonists |
| US9567337B2 (en) | 2013-12-20 | 2017-02-14 | Gilead Calistoga Llc | Process methods for phosphatidylinositol 3-kinase inhibitors |
| JP2017500319A (ja) | 2013-12-20 | 2017-01-05 | ギリアード カリストガ エルエルシー | （ｓ）−２−（１−（９ｈ−プリン−６−イルアミノ）プロピル）−５−フルオロ−３−フェニルキナゾリン−４（３ｈ）−オンの塩酸塩の多形形態 |
| WO2015191726A1 (en) | 2014-06-13 | 2015-12-17 | Gilead Sciences, Inc. | Phosphatidylinositol 3-kinase inhibitors |
| US12297505B2 (en) | 2014-07-14 | 2025-05-13 | Veracyte, Inc. | Algorithms for disease diagnostics |
| US20170335396A1 (en) | 2014-11-05 | 2017-11-23 | Veracyte, Inc. | Systems and methods of diagnosing idiopathic pulmonary fibrosis on transbronchial biopsies using machine learning and high dimensional transcriptional data |
| EP3018127A1 (en) | 2014-11-07 | 2016-05-11 | Bayer Pharma Aktiengesellschaft | Synthesis of copanlisib and its dihydrochloride salt |
| EP3018131A1 (en) * | 2014-11-07 | 2016-05-11 | Bayer Pharma Aktiengesellschaft | Synthesis of copanlisib and its dihydrochloride salt |
| CN107864625B (zh) | 2015-03-09 | 2021-05-28 | 拜耳制药股份公司 | 含有取代的2,3-二氢咪唑并[1,2-c]喹唑啉的组合产品 |
| CN105130998B (zh) * | 2015-09-25 | 2017-07-28 | 苏州立新制药有限公司 | 库潘尼西的制备方法 |
| CN105130997B (zh) * | 2015-09-25 | 2017-12-05 | 苏州明锐医药科技有限公司 | 一种库潘尼西的制备方法 |
| CA3016584A1 (en) | 2016-03-08 | 2017-09-14 | Bayer Pharma Aktiengesellschaft | 2-amino-n-[7-methoxy-2,3-dihydroimidazo-[1,2-c]quinazolin-5-yl]pyrimidine-5-carboxamides |
| EP3219329A1 (en) | 2016-03-17 | 2017-09-20 | Bayer Pharma Aktiengesellschaft | Combinations of copanlisib |
| US10927417B2 (en) | 2016-07-08 | 2021-02-23 | Trustees Of Boston University | Gene expression-based biomarker for the detection and monitoring of bronchial premalignant lesions |
| CN109729716B (zh) | 2016-09-23 | 2022-03-15 | 拜耳制药股份公司 | Pi3k-抑制剂的组合产品 |
| CA3045041A1 (en) | 2016-12-14 | 2018-06-21 | Tarveda Therapeutics, Inc. | Hsp90-targeting conjugates and formulations thereof |
| EP3585437B1 (en) | 2017-02-24 | 2022-12-21 | Bayer Pharma Aktiengesellschaft | Combinations of copanlisib with anti-pd-1 antibody |
| EP3645005A1 (en) | 2017-06-28 | 2020-05-06 | Bayer Consumer Care AG | Combination of a pi3k-inhibitor with an androgen receptor antagonist |
| EP3498266A1 (en) | 2017-12-15 | 2019-06-19 | Bayer Consumer Care AG | Formulations of copanlisib |
| PE20200958A1 (es) | 2017-09-08 | 2020-09-24 | Bayer Consumer Care Ag | Solido liofilizado de copanlisib |
| EP3684772B1 (en) * | 2017-09-20 | 2023-12-06 | ABM Therapeutics Corporation | Cyclic iminopyrimidine derivatives as kinase inhibitors |
| WO2019073031A1 (en) | 2017-10-13 | 2019-04-18 | INSERM (Institut National de la Santé et de la Recherche Médicale) | POLYTHERAPY OF PANCREATIC CANCER |
| WO2019101871A1 (en) | 2017-11-23 | 2019-05-31 | Inserm (Institut National De La Sante Et De La Recherche Medicale) | A new marker for predicting the sensitivity to pi3k inhibitors |
| WO2019105734A1 (en) | 2017-11-28 | 2019-06-06 | Bayer Consumer Care Ag | Combinations of copanlisib |
| WO2019105835A1 (en) | 2017-11-29 | 2019-06-06 | Bayer Consumer Care Ag | Combinations of copanlisib and anetumab ravtansine |
| WO2019197269A1 (en) | 2018-04-11 | 2019-10-17 | Bayer Aktiengesellschaft | Combinations of copanlisib with triazolone derivatives and their use in the treatment of cancer |
| CN112789279B (zh) * | 2018-07-27 | 2023-09-29 | 上海翰森生物医药科技有限公司 | 含三并环类衍生物抑制剂、其制备方法和应用 |
| CN109053554B (zh) * | 2018-08-01 | 2020-07-28 | 江苏八巨药业有限公司 | 一种使用催化剂合成3-乙酰吡啶的方法 |
| EP3843743A1 (en) | 2018-08-28 | 2021-07-07 | Bayer AS | Combination of pi3k-inhibitors and targeted thorium conjugates |
| EP3866805A1 (en) | 2018-10-16 | 2021-08-25 | Bayer Aktiengesellschaft | Combination of atr kinase inhibitors with 2,3-dihydroimidazo[1,2-c]quinazoline compounds |
| CA3118493A1 (en) | 2018-11-05 | 2020-05-14 | Iovance Biotherapeutics, Inc. | Expansion of tils utilizing akt pathway inhibitors |
| US20220040324A1 (en) | 2018-12-21 | 2022-02-10 | Daiichi Sankyo Company, Limited | Combination of antibody-drug conjugate and kinase inhibitor |
| WO2020164997A1 (en) | 2019-02-12 | 2020-08-20 | Bayer Aktiengesellschaft | Combination of pi3k-inhibitors |
| CN114621236B (zh) * | 2022-04-25 | 2024-06-18 | 河南湾流生物科技有限公司 | 一种喹啉类饲料添加剂的制备方法 |
| WO2025087879A2 (en) | 2023-10-23 | 2025-05-01 | Institut National de la Santé et de la Recherche Médicale | Suppressing the pi3kgamma/akt signalling pathway for the treatment of acute myeloid leukemia |
Family Cites Families (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US3644354A (en) * | 1968-09-16 | 1972-02-22 | Sandoz Ag | 5-substituted-2 3-dihydroimidazo(1 2-c)quinazolines |
| US4287341A (en) | 1979-11-01 | 1981-09-01 | Pfizer Inc. | Alkoxy-substituted-6-chloro-quinazoline-2,4-diones |
| NZ234186A (en) * | 1989-07-07 | 1991-10-25 | Janssen Pharmaceutica Nv | Imidazo quinazolin-one derivatives and pharmaceutical compositions |
| CN1033644C (zh) * | 1993-01-02 | 1996-12-25 | 瑞安大药厂股份有限公司 | 3-取代甲基-2，3-二氢咪唑并[1，2-c]喹唑啉衍生物，其制备与用途 |
| EP0771204A4 (en) | 1994-08-12 | 1999-10-20 | Pro Neuron Inc | METHOD FOR TREATING SEPSIS OR FLAMMABLE DISEASES WITH OXYPURINE NUCLEOSIDES |
| EP0885192B8 (en) * | 1996-01-29 | 2012-05-16 | The United States of America, Represented by the Secretary, Department of Health and Human Services | Dihydropyridine-, pyridine-, benzopyran- one- and triazoloquinazoline derivative, their preparation and their use as adenosine receptor antagonists |
| US5932584A (en) * | 1997-05-06 | 1999-08-03 | National Science Council | Optically active 2,3-dihydroimidazo(1,2-C) quinazoline derivatives, the preparation and antihypertensive use thereof |
| ATE502941T1 (de) | 2000-04-25 | 2011-04-15 | Icos Corp | Hemmer der menschlichen phosphatidyl-inositol-3- kinase delta |
| KR100774855B1 (ko) * | 2000-04-27 | 2007-11-08 | 아스텔라스세이야쿠 가부시키가이샤 | 축합 헤테로아릴 유도체 |
-
2003
- 2003-09-18 HR HRP20131159A patent/HRP20131159B1/hr not_active IP Right Cessation
- 2003-09-18 CN CNB038233673A patent/CN100384846C/zh not_active Expired - Lifetime
- 2003-09-18 EP EP03788908A patent/EP1549652B1/en not_active Expired - Lifetime
- 2003-09-18 US US10/527,376 patent/US7511041B2/en not_active Expired - Lifetime
- 2003-09-18 EP EP08075839A patent/EP2042504B1/en not_active Expired - Lifetime
- 2003-09-18 ES ES08075839T patent/ES2367141T3/es not_active Expired - Lifetime
- 2003-09-18 CA CA2499134A patent/CA2499134C/en not_active Expired - Lifetime
- 2003-09-18 SI SI200332036T patent/SI2042504T1/sl unknown
- 2003-09-18 BR BRPI0314830A patent/BRPI0314830B8/pt not_active IP Right Cessation
- 2003-09-18 ES ES03788908T patent/ES2312843T3/es not_active Expired - Lifetime
- 2003-09-18 PT PT03788908T patent/PT1549652E/pt unknown
- 2003-09-18 HR HRP20050375AA patent/HRP20050375B1/hr not_active IP Right Cessation
- 2003-09-18 SI SI200331490T patent/SI1549652T1/sl unknown
- 2003-09-18 RU RU2005113165/04A patent/RU2326881C9/ru active
- 2003-09-18 PT PT08075839T patent/PT2042504E/pt unknown
- 2003-09-18 AT AT03788908T patent/ATE411996T1/de active
- 2003-09-18 PL PL375935A patent/PL226562B1/pl unknown
- 2003-09-18 DK DK03788908T patent/DK1549652T3/da active
- 2003-09-18 MX MXPA05001808A patent/MXPA05001808A/es active IP Right Grant
- 2003-09-18 WO PCT/EP2003/010377 patent/WO2004029055A1/en not_active Ceased
- 2003-09-18 UA UAA200504176A patent/UA82205C2/uk unknown
- 2003-09-18 JP JP2004538935A patent/JP4790266B2/ja not_active Expired - Lifetime
- 2003-09-18 AU AU2003293310A patent/AU2003293310B2/en not_active Expired
- 2003-09-18 AT AT08075839T patent/ATE511510T1/de active
- 2003-09-18 DK DK08075839.4T patent/DK2042504T3/da active
- 2003-09-18 NZ NZ539062A patent/NZ539062A/en not_active IP Right Cessation
- 2003-09-18 KR KR1020057005434A patent/KR101059652B1/ko not_active Expired - Lifetime
- 2003-09-18 DE DE60324296T patent/DE60324296D1/de not_active Expired - Lifetime
- 2003-09-29 MY MYPI20033701A patent/MY140756A/en unknown
- 2003-09-29 AR ARP030103542A patent/AR041426A1/es active IP Right Grant
- 2003-09-29 PE PE2003000986A patent/PE20050089A1/es active IP Right Grant
- 2003-09-29 TW TW092126767A patent/TWI327570B/zh not_active IP Right Cessation
- 2003-09-29 UY UY28001A patent/UY28001A1/es active IP Right Grant
-
2005
- 2005-02-14 IL IL166855A patent/IL166855A/en active IP Right Grant
- 2005-04-25 ZA ZA200503306A patent/ZA200503306B/en unknown
- 2005-04-27 NO NO20052076A patent/NO331457B1/no not_active IP Right Cessation
- 2005-04-28 EC EC2005005768A patent/ECSP055768A/es unknown
- 2005-04-29 MA MA28247A patent/MA27483A1/fr unknown
-
2009
- 2009-01-09 CY CY20091100017T patent/CY1109790T1/el unknown
- 2009-03-30 US US12/414,257 patent/US8129386B2/en not_active Expired - Lifetime
- 2009-07-01 AR ARP090102458A patent/AR072458A2/es not_active Application Discontinuation
-
2011
- 2011-02-07 EC EC2011005768A patent/ECSP11005768A/es unknown
- 2011-08-10 CY CY20111100771T patent/CY1112174T1/el unknown
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| AR041426A1 (es) | Derivados de azol-pirimidina condensados; uso del compuesto para la preparacion de medicamentos | |
| PE20221264A1 (es) | Inhibidores de egfr | |
| AR074435A1 (es) | Derivados de 1,3-benzotiazol, medicamentos que los contienen y uso de los mismos en el tratamiento del cancer. | |
| PE20171341A1 (es) | Compuestos de pirazina para el tratamiento de enfermedades infecciosas | |
| CO6231028A2 (es) | Compuestos y composiciones como inhibidores de la proteina quinasa | |
| AR053232A1 (es) | Derivados de piridina condensadas, composiciones farmaceuticas que los contienen y su empleo en la fabricacion de agentes terapeuticos antiinflamatorios y para el tratamiento de enfermedades relacionadas con el sistema inmunologico. | |
| EA201891463A1 (ru) | ПРОИЗВОДНЫЕ ПИРАЗОЛО[1,5-a]ПИРАЗИН-4-ИЛА В КАЧЕСТВЕ ИНГИБИТОРОВ ЯНУС-КИНАЗЫ (JAK) | |
| AR102094A1 (es) | Inhibidores de proteínas kras con una mutación g12c | |
| PE20050691A1 (es) | Proceso para preparar carboxamidas 2-aminotiazol-5-aromaticas como inhibidores de la cinasa | |
| PE20070218A1 (es) | COMPUESTOS DE CICLOALQUILO AMINO-HIDANTOINA Y USO DE ESTOS PARA LA MODULACION DE ß-SECRETASA | |
| AR086983A1 (es) | Derivados de azetidinil fenil, piridil o pirazinil carboxamida como inhibidores de jak | |
| ATE463483T1 (de) | 6-substituierte isochinolinderivate als rock-1- inhibitoren | |
| AR065531A1 (es) | Derivados de pirimidina, procesos de obtencion y composiciones farmaceuticas. | |
| PE20191245A1 (es) | Compuestos de tiazolcarboxamidas y piridinacarboxamida utiles como inhibidores de quinasa pim | |
| PE20070855A1 (es) | Derivados de 4-amino-pirrolotriazina sustituida como inhibidores de quinasas | |
| AR039540A1 (es) | Compuestos microbicidas con contenido de pirimidina o triazina | |
| TW200833686A (en) | Fused bicyclic derivatives of 2,4-diaminopyrimidine as ALK and c-Met inhibitors | |
| EA201592252A1 (ru) | 6,7-ДИГИДРОПИРАЗОЛО[1,5-a]ПИРАЗИН-4(5H)-ОНОВЫЕ СОЕДИНЕНИЯ И ИХ ПРИМЕНЕНИЕ В КАЧЕСТВЕ ОТРИЦАТЕЛЬНЫХ АЛЛОСТЕРИЧЕСКИХ МОДУЛЯТОРОВ РЕЦЕПТОРОВ MGLUR2 | |
| AR042023A1 (es) | Derivados de fenil o heteroaril amino alcano | |
| AR064318A1 (es) | Compuesto y composicion derivada de aril sulfamida, uso del compuesto y proceso para la preparacion del compuesto | |
| BR112016019462B8 (pt) | Compostos heterocïclicos tricïclicos como inibidores de fosfoinosotida 3-cinase | |
| RU2015116749A (ru) | Антагонисты mglu2/3 для лечения аутических расстройств | |
| JP2005537323A5 (es) | ||
| PE20212178A1 (es) | Compuestos de hexahidro-1h-pirazino[1,2-a]pirazina para el tratamiento de una enfermedad autoinmunitaria | |
| JP2016540803A5 (es) |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FG | Grant, registration |